Table 2 Trabectedin exposure per age group

From: Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

  

⩾60 Years

 
 

<60 Years

⩾60 Years

⩾70 Years

Total

 

n

%

n

%

n

%

n

%

 

267

76

83

24

24

7

350

100

Time on treatment (weeks)

Median (range)

10

(3.0–181.1)

12

(3.0–236.7)

7.5

(3.0–37.3)

10

(3.0–236.7)

Cycles per patient

Median (range)

3

(1–48)

3

(1–59)

2

(1–12)

3

(1–59)

Patients with ⩾7 cycles

 

67

25.1

23

27.7

3

12.5

90

25.7

Patients with ⩾10 cycles

 

49

18.4

10

12.0

1

4.2

59

16.9

Dose intensity (mg m –2 per week)

Median (range)

0.42

(0.2–0.6)

0.40

(0.2–0.5)

0.41

(0.3–0.5)

0.41

(0.2–0.6)

Relative dose intensity (%)

Median (range)

87

(39–120)

87

(39–101)

89

(57–100)

87

(39–120)

Back to article page